What is key point 1 about "Septerna president Bhatt sells $115,860 in shares"?

Elizabeth Bhat sold $115,860 in Septerna shares following a 370% stock surge

What is key point 2 about "Septerna president Bhatt sells $115,860 in shares"?

The sales were part of a pre-planned Rule 10b5-1 trading strategy

What is key point 3 about "Septerna president Bhatt sells $115,860 in shares"?

Septerna will present Phase 1 clinical trial data for SEP-631 in 2026

What is key point 4 about "Septerna president Bhatt sells $115,860 in shares"?

Analysts maintain positive ratings with price targets ranging from $35 to $43

What is key point 5 about "Septerna president Bhatt sells $115,860 in shares"?

Septerna appointed Mark A. Wilson as Chief Legal Officer from Nektar Therapeutics

2/21/2026 | USA | economy | ✓ Verified - investing.com

Septerna president Bhatt sells $115,860 in shares

#Septerna #Elizabeth Bhat #insider trading #biotech stocks #SEP-631 #Phase 1 clinical trial #NASDAQ:SEPN #stock sales

📌 Key Takeaways

Elizabeth Bhat sold $115,860 in Septerna shares following a 370% stock surge
The sales were part of a pre-planned Rule 10b5-1 trading strategy
Septerna will present Phase 1 clinical trial data for SEP-631 in 2026
Analysts maintain positive ratings with price targets ranging from $35 to $43
Septerna appointed Mark A. Wilson as Chief Legal Officer from Nektar Therapeutics

📖 Full Retelling

Septerna Inc. (NASDAQ:SEPN) President and COO Elizabeth Bhat sold 4,000 shares of common stock on February 18, 2026, for a total of $115,860, as part of a pre-planned trading strategy. The biotech executive executed the sales in two tranches at weighted average prices ranging from $28.4594 to $29.5831, coinciding with a remarkable 370% surge in the company's stock value over the past year. The transactions were conducted under a Rule 10b5-1 sales plan adopted on October 20, 2025, which allows insiders to set trading plans in advance to avoid accusations of insider trading. On the same day as the sales, Bhatt also exercised options to acquire 4,000 shares of Septerna common stock at $6.81 per share, totaling $27,240, leaving her with 174,209 direct shares following these transactions. The company, currently valued at $1.22 billion, maintains a 'GREAT' financial health score according to InvestingPro, reflecting its solid financial position amid ongoing developments in its drug discovery pipeline.

🏷️ Themes

Corporate Leadership, Biotechnology, Financial Markets, Healthcare Innovation

Entity Intersection Graph

No entity connections available yet for this article.

Deep Analysis

Why It Matters

The sale by Septerna's president signals confidence in the company while providing liquidity for the executive. It also highlights the stock's strong performance and the use of a pre‑planned sales strategy.

Context & Background

Septerna's stock surged 370% in the past year
President Elizabeth Bhatt sold 4,000 shares under a Rule 10b5-1 plan
She also exercised options to buy 4,000 shares at $6.81 each

What Happens Next

Investors will watch for the Phase 1 trial results presented at the 2026 American Academy of Allergy Asthma & Immunology Annual Meeting, which could influence the stock price. Analysts may adjust price targets as new data emerges.

Frequently Asked Questions

What is a Rule 10b5-1 sales plan?

A pre‑established plan that allows insiders to sell shares at set times, protecting them from insider trading allegations.

How many shares does Bhatt own after the transactions?

She directly owns 174,209 shares of Septerna.

What is the significance of the Phase 1 trial?

It tests the safety and dosage of SEP-631, a drug for chronic spontaneous urticaria, and could open new markets for the company.

Original Source

              try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Trump imposes new 10% global levy as SCOTUS strikes down sweeping tariffs Stocks end higher after SCOTUS tariff ruling, S&P 500 snaps two-week losing streak Gold rises, silver jumps after disappointing economic data, SCOTUS tariff ruling U.S. military operation in Iran "likely at this stage," Raymond James says (South Africa Philippines Nigeria) Septerna president Bhatt sells $115,860 in shares By Investing.com Insider Trading Published 02/20/2026, 09:52 PM Septerna president Bhatt sells $115,860 in shares 0 SEPN 0.74% Septerna, Inc. (NASDAQ:SEPN) President and COO Elizabeth Bhatt sold 4,000 shares of common stock on February 18, 2026, for a total of $115,860. The sales were executed in two tranches at weighted average prices ranging from $28.4594 to $29.5831. The timing follows a remarkable 370% surge in the stock over the past year. The transaction was executed under a Rule 10b5-1 sales plan adopted on October 20, 2025. On the same day, Bhatt also exercised options to acquire 4,000 shares of Septerna common stock at a price of $6.81 per share, for a total value of $27,240. Following these transactions, Bhatt directly owns 174,209 shares of Septerna, Inc. The biotech company, valued at $1.22 billion, maintains a "GREAT" financial health score according to InvestingPro , which offers detailed analysis including 10 additional ProTips for investors seeking deeper insights into SEPN’s prospects. In other recent news, Septerna Inc. announced it will present data from its Phase 1 clinical trial of SEP-631 at the American Academy of Allergy Asthma & Immunology Annual Meeting in 2026. The trial involves SEP-631, an oral small molecule developed for chronic spontaneous urticaria and other mast cell-driven diseases. On the financial front, H.C. Wainwright raised its price target for Septerna to $35, maintaining a Buy rating, due to adjustments in their valuation model. Additionally, Jones Trading initiated coverage of...
            

Read full article at source

Source

investing.com